STOCK TITAN

Teladoc (NYSE: TDOC) executive boosts holdings after stock unit vesting and tax sale

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Teladoc Health President U.S. Group Health Kelly Bliss reported routine equity compensation activity. On June 1, 2026, she exercised performance and restricted stock units that converted into a total of 15,310 shares of common stock at a conversion price of $0.00 per share.

On June 2, 2026, she sold 7,679 common shares at $7.627 per share to cover the tax withholding obligation tied to these vestings, according to the footnotes. After these transactions, she directly owned 92,378 Teladoc shares, indicating a net increase in her equity position.

Positive

  • None.

Negative

  • None.
Insider Bliss Kelly
Role President, U.S. Group Health
Sold 7,679 shs ($59K)
Type Security Shares Price Value
Sale Common Stock 7,679 $7.627 $59K
Exercise Performance Stock Units 1,300 $0.00 --
Exercise Restricted Stock Units 4,858 $0.00 --
Exercise Restricted Stock Units 9,152 $0.00 --
Exercise Common Stock 1,300 $0.00 --
Exercise Common Stock 4,858 $0.00 --
Exercise Common Stock 9,152 $0.00 --
Holdings After Transaction: Common Stock — 92,378 shares (Direct, null); Performance Stock Units — 9,098 shares (Direct, null); Restricted Stock Units — 14,577 shares (Direct, null)
Footnotes (1)
  1. Performance stock units convert to shares of TDOC common stock on a one-for-one basis. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards. On March 1, 2026, the reporting person earned 15,596 performance stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter. On March 19, 2024, the reporting person was granted 58,300 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025. On March 1, 2025, the reporting person was granted 109,832 restricted stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Shares sold 7,679 shares Common stock sold on June 2, 2026
Sale price $7.627 per share Price for 7,679 Teladoc shares sold
Shares from unit vesting 15,310 shares Common shares received from exercised stock units on June 1, 2026
Post-transaction holdings 92,378 shares Direct Teladoc common stock owned after transactions
Performance stock units earned 15,596 units Earned on March 1, 2026
RSU grant 2024 58,300 units Restricted stock units granted March 19, 2024
RSU grant 2025 109,832 units Restricted stock units granted March 1, 2025
Performance stock units financial
"Performance stock units convert to shares of TDOC common stock on a one-for-one basis."
Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.
Restricted stock units financial
"Restricted stock units convert to shares of TDOC common stock on a one-for-one basis."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligation financial
"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards."
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
Sale in open market or private transaction financial
"transaction_code_description: Sale in open market or private transaction"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bliss Kelly

(Last)(First)(Middle)
C/O TELADOC HEALTH, INC.,
155 E 44TH ST, SUITE 1700

(Street)
NEW YORK NEW YORK 10017

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President, U.S. Group Health
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/01/2026M1,300A(1)86,047D
Common Stock06/01/2026M4,858A(2)90,905D
Common Stock06/01/2026M9,152A(2)100,057D
Common Stock06/02/2026S7,679(3)D$7.62792,378D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Stock Units(1)06/01/2026M1,300 (4) (4)Common Stock1,300$09,098D
Restricted Stock Units(2)06/01/2026M4,858 (5) (5)Common Stock4,858$014,577D
Restricted Stock Units(2)06/01/2026M9,152 (6) (6)Common Stock9,152$064,070D
Explanation of Responses:
1. Performance stock units convert to shares of TDOC common stock on a one-for-one basis.
2. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.
3. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.
4. On March 1, 2026, the reporting person earned 15,596 performance stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
5. On March 19, 2024, the reporting person was granted 58,300 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.
6. On March 1, 2025, the reporting person was granted 109,832 restricted stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Remarks:
/s/ Adam C. Vandervoort, Attorney-in-Fact06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Teladoc (TDOC) executive Kelly Bliss report?

Kelly Bliss reported exercising stock units that converted into 15,310 Teladoc shares and selling 7,679 shares. The sale was specifically to cover tax withholding for recently vested performance and restricted stock unit awards, leaving her with a higher overall shareholding after the transactions.

How many Teladoc (TDOC) shares did Kelly Bliss sell and at what price?

Kelly Bliss sold 7,679 Teladoc common shares at $7.627 per share. Footnotes explain the sale was made to satisfy tax withholding obligations arising from vesting of her performance and restricted stock unit awards, rather than a discretionary open-market liquidation.

Did Kelly Bliss increase or decrease her Teladoc (TDOC) shareholdings?

Kelly Bliss increased her Teladoc shareholdings overall. She received 15,310 shares from vested stock units and sold 7,679 shares for tax withholding, ending with 92,378 directly owned shares, which is higher than her reported holdings before these compensation-related transactions.

What types of equity awards did Kelly Bliss have at Teladoc (TDOC)?

Her equity awards included performance stock units and restricted stock units, each converting to Teladoc common stock on a one-for-one basis. Footnotes detail prior grants, including 15,596 performance stock units earned and multiple restricted stock unit grants vesting over quarterly installments after initial vesting dates.

Why were Teladoc (TDOC) shares sold in Kelly Bliss’s Form 4 filing?

The shares were sold to cover tax withholding obligations related to vesting stock awards. A footnote states the 7,679 Teladoc shares were sold in connection with the tax requirements from vested performance and restricted stock units, rather than a discretionary portfolio sale by the executive.

How many Teladoc (TDOC) shares does Kelly Bliss hold after the Form 4 transactions?

Following the reported transactions, Kelly Bliss directly owned 92,378 Teladoc common shares. This figure reflects the net effect of receiving 15,310 shares from vested stock units and selling 7,679 shares to satisfy associated tax withholding obligations as detailed in the filing footnotes.